New Omicron subvariant BA.2.86: A master of immune escape but not taking over yet

Researchers have isolated a new SARS-CoV-2 Omicron subvariant, BA.2.86, revealing its ability to escape neutralizing antibodies five-fold greater than its ancestor strain. Despite its enhanced immune evasion capabilities, BA.2.86 has not shown a significant difference in spread compared to other current variants.

Canopy Growth Dilutes Its Stock After Big Rally

Canopy Growth Announces Financing to Further Strengthen Balance Sheet Including Approximately US$50 Million of New Gross Proceeds C$27.5 Millon of Debt Extended from 2025 to

May 3, 2024

Dupilumab Proves Effective in Chronic Spontaneous Urticaria

BOSTON — Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy. The

October 28, 2024

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.